No Data
Express News | xinjiang bai hua cun pharma tech: Controlling shareholder signs a concerted action agreement.
Report for the third quarter of 2024 of Xinjiang Baihuacun Pharmaceutical Group Co., Ltd.
Express News | xinjiang bai hua cun pharma tech: net income in the first three quarters was 23.9532 million yuan, a year-on-year increase of 35.39%.
xinjiang bai hua cun pharma tech (600721.SH): the net income in the first three quarters was 23.9532 million yuan, a year-on-year increase of 35.39%.
On October 24, Bai Hua Cun Pharma Tech (600721.SH) announced that the company's revenue for the first three quarters was 0.291 billion yuan, a year-on-year increase of 9.38%; the net income attributable to shareholders of the listed company was 23.9532 million yuan, a year-on-year increase of 35.39%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 21.7014 million yuan, a year-on-year increase of 32.52%; and the basic earnings per share was 0.0627 yuan.
The CRO sector of A shares trended lower, with chempartner pharmatech falling more than 8%.
Gelonghui September 26th | Chempartner Pharmatech fell by 8.21%, Xinjiang Bai Hua Cun Pharma Tech fell by 5.26%, Zhejiang Canaan Technology fell by 2.84%, Wanbang Pharma, Pharmaron, and Noushige all dropped by more than 2%.
Concept stocks related to CRO in A-shares continue to rise, with chempartner pharmatech hitting the limit up.
Gelonghui on September 23: Chempartner Pharmatech, xinjiang bai hua cun pharma tech both hit the daily limit up, prior to hainan shuangcheng pharmaceuticals hitting the limit up, henan taloph pharmaceutical stock, wuxi apptec, guangxi hechi chemical all rose more than 5%.
No Data
No Data